Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Supplemental Examination: BIO Comments on Patent Reform

Mar 25 2012

...

BIO's Testimony to the House Appropriations, Labor HHS Subcommittee on the President's FY 2013 Budget Request for the National Institutes of Health (NIH)

Mar 20 2012

...

BIO Supports the JOBS Act (H.R. 3606)

Mar 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.

PCORI Draft National Priorities and Research Agenda: BIO's Comments

Mar 14 2012

...

AIA Oath or Declaration: BIO Comments

Mar 7 2012

...

Spurring Job Growth Through Capital Formation While Protecting Investors

Mar 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.

2013 Draft Call Letter: BIO's Comments to CMS

Mar 1 2012

...

Letter to the Texas Health and Human Services Commission Regarding Proposed Specialty Pharmacy Rule

Mar 1 2012
  Comments on a proposed Texas Administrative Code that would classify biologics as specialty drugs. 

Biologics: BIO Comments on EMA 'Concept Paper on the Revision of the Guideline on Similar Biological medicinal Product"

Feb 28 2012

...

Good Guidance Practices: FDA Report on Good Guidance Practices: Improving Efficiency and Transparency

Feb 28 2012

...